The Human Immunology and Cancer Program (HICP) is a multifaceted basic and clinical scientific endeavor devoted to advancing understanding of the pathogenesis of primary (AL) amyloidosis and developing innovative diagnostic and therapeutic means; the ultimate goal is to eventually diminish or eradicate the calamitous effects of this disease. Our research efforts are directed towards the precise identification and characterization, through immunological, biochemical, and molecular biological techniques, of the protein components that are largely responsible for the devastating manifestations of this disorder. Based on this knowledge, we also are formulating innovative diagnostic and therapeutic approaches for patients with AL amyloidosis. Through use of both in vitro and in vivo experimental models, various chemical and biological substances are being tested to determine their capacity to break down amyloid deposits. Because certain maladies, such as Alzheimer's disease, also are caused by the abnormal deposition of other types of proteins, we anticipate that the results of our work will be beneficial to individuals with these conditions, as well.
The University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, TN 37920
Phone: (865) 305-9167
Fax: (865) 305-6865